Vetter once again earned the 2024 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service for big pharma, small pharma and overall respondents. The award reaffirms Vetter’s mission to provide the highest possible quality and value for pharma and biotech companies worldwide in their development, manufacturing as well as assembly and packaging of injectables.
“We are dedicated to embodying the characteristics that this award highlights to provide the best to our customers and their patients. We leverage our decades of experience and the expertise of our 6,300 employees to do so,” shared Vetter’s Managing Director Peter Soelkner. “To be recognized once again by the CDMO Leadership Awards is a testament that we are living out our company mission in the work we do every day.”
In fact, with a result of € 1,002 million in completed orders over the past financial year, Vetter has successfully reached to surpass the one billion sales threshold. This confirms the strong commitment to stable customer relationships and ongoing sustainable growth.
The awards program provides a unique representation of the level of excellence offered to customers, as honorees are selected based on customer evaluations of the CDMOs they have worked with over the past 18 months. Now in its 13th year, Outsourced Pharma and Life Science Leader’s CDMO Leadership Awards provide its audiences with accurate and dependable customer feedback to help them select a reputable partner for their development, manufacturing and packaging needs.
“As drug owners are increasingly counting on CDMOs to provide unwavering access to supply chains, appropriate infrastructure, and proven processes, the CDMO Leadership Awards reflect our commitment to act as their outsourcing partner of choice, said Vetter Managing Director Thomas Otto. “We are proud that this further instills a sense of confidence in our trustworthiness among our current and future customers.”
Louis Garguilo, Chief Editor and Conference Chair of Outsourced Pharma added: “Drug and therapy sponsors had much to be concerned with during the last 12 months or so. There was still supply-chain uncertainty, ever-growing novelty in platforms and processes requiring new skill sets and technologies, and the speed of everything seemed to accelerate. Through it all, CDMOs stayed focused and also adapted to customer and market needs. Those best at serving their customers and thus patients are recognized as the 2024 CDMO Leadership Award winners.”
